C$60 million Series A financing will enable Tilray to increase production capacity and expand distribution in North America and Europe
TORONTO – Tilray, a global pioneer in medical cannabis research, cultivation, processing and distribution, today announced the completion of its Series A funding round totaling C$60 million. The round was comprised of a group of leading global institutional investors.
Tilray will use the new funding to increase its existing production capacity in North America, to continue to build its European Union campus in Portugal, and to expand availability of its products to more patients and pharmacies around the globe. The terms of the Series A funding round, including Tilray’s valuation, were not disclosed.
Tilray, federally licensed in Canada and Europe, currently sells pharmaceutical-grade, GMP-certified medical cannabis products to tens of thousands of patients in eight countries. The company supplies hospitals, pharmacies and pharmaceutical distributors on four continents, and has signed supply agreements with NOWEDA, one of Germany’s largest pharmaceutical wholesalers, and Shoppers Drug Mart, Canada’s largest pharmacy chain.
Since its founding in 2014, Tilray has been wholly-owned and solely funded by Privateer Holdings, the world’s leading private equity firm investing exclusively in legal cannabis. Tilray’s Series A funding round marks the first time that outside investors have invested directly into a Privateer Holdings portfolio company. With its Series A funding and incorporation, Tilray is positioned to operate and finance its growth independent of Privateer Holdings.
Cowen served as sole placement agent and Cooley LLP served as legal counsel for the transaction.
Tilray is a global pioneer in the research, cultivation, production and distribution of medical cannabis and cannabinoids. Tilray was the first licensed producer of medical cannabis in the world to have its facility Good Manufacturing Practices (GMP) certified in accordance with European Medicine Agency (EMA) standards.
The company currently serves tens of thousands of patients, physicians, pharmacies, governments, hospitals, and researchers in eight countries spanning four continents through its affiliated entities in Australia and New Zealand (Tilray Australia New Zealand Pty Ltd), Canada (Tilray Canada Ltd), Germany (Tilray Deutschland GmbH), and Portugal (Tilray Portugal Unipessoal Lda).
For further information:
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Notify me of follow-up comments by email.
Notify me of new posts by email.
by Colton Griffin Last month I was in San Francisco for the National Cannabis Industry Association meeting, where I dropped in on a symposium about environmental sustainability in our industry. I ended up in a fascinating discussion among people representing different parts of the cannabis supply chain: a cultivator, a packager, a distributor, an attorney—and…
THE UK Food Standards Agency has set a new deadline of the end of February for the submission of data to support some CBD Novel Food applications, it has emerged. This comes as one UK company – British Cannabis – has been notified by the FSA that its 15 Novel Food CBD dossiers, spanning over…
The world is changing. Consumers are changing. Marketing has to change as well – even marketing in the cannabis industry. The reality today is if cannabis and cannabis-related businesses don’t keep up, they’ll lose sales, market share, and future growth potential to competitors. With that in mind, below are five of the key digital marketing…
Seven months into the legal recreational marijuana landscape, Connecticut’s previously underground cannabis community is enjoying public consumption parties where growers show off flower specimens in what they believe is a gray area in the law. Groups such as the CT CannaWarriors, High Bazaar and the New England Craft Cannabis Alliance, which have been advocating for years for full legalization…